Our study provided a strong evidence that serum CEA did not has a guiding role for ACT in stage IIA colon cancer and stage IIA disease with elevated pretreatment serum CEA should not be treated with ACT. This evidence concerns the gene CEACAM5 and colonic neoplasm.